Last reviewed · How we verify
NCT07433400: EVOLALPh1
Long-term Progression of Patients Treated and Monitored for Relapsed or Refractory Ph+ ALL
trial in Ph Positive ALL in 500 participants. Currently enrolling.
31 December 2035
Quick facts
| Lead sponsor | Group for Research in Adult Acute Lymphoblastic Leukemia |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 500 |
| Start date | 29 August 2025 |
| Primary completion | 31 December 2035 |
| Estimated completion | 31 December 2035 |
| Sites | 1 location across France |
Conditions studied
- Ph Positive ALL — all drugs for Ph Positive ALL →
Sponsor
Group for Research in Adult Acute Lymphoblastic Leukemia
Who can join
18 and older, any sex, with Ph Positive ALL. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objective of this retrospective study is to examine the outcome of patients who relapse with Ph+ ALL and to potentially identify response profiles in order toadvance the treatment regimens that can be offered.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07433400
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Group for Research in Adult Acute Lymphoblastic Leukemia trials
Trials by the same sponsor.
- NCT03751072 — Efficacy and Toxicity of Blinatumomab in the French ATU for Adult BCP-ALL R/R, or With MRD+ (FRENCH-CYTO) · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07433400 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Group for Research in Adult Acute Lymphoblastic Leukemia
- Last refreshed: 25 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07433400.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing